دورية أكاديمية
Comparative efficacy of brolucizumab, half-dose photodynamic therapy, and aflibercept in managing chronic central serous chorioretinopathy.
| العنوان: | Comparative efficacy of brolucizumab, half-dose photodynamic therapy, and aflibercept in managing chronic central serous chorioretinopathy. |
|---|---|
| المؤلفون: | Huang YT; Department of Ophthalmology, Eye Center, China Medical University Hospital, 2 Yuh-Der Road, Taichung City, 40447, Taiwan., Tien PT; Department of Ophthalmology, Eye Center, China Medical University Hospital, 2 Yuh-Der Road, Taichung City, 40447, Taiwan.; School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan., Chen PY; Department of Ophthalmology, Eye Center, China Medical University Hospital, 2 Yuh-Der Road, Taichung City, 40447, Taiwan., Yang CL; Department of Ophthalmology, Eye Center, China Medical University Hospital, 2 Yuh-Der Road, Taichung City, 40447, Taiwan., Chen SN; Department of Ophthalmology, Eye Center, China Medical University Hospital, 2 Yuh-Der Road, Taichung City, 40447, Taiwan. sanchen52@gmail.com.; School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan. sanchen52@gmail.com. |
| المصدر: | Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie [Graefes Arch Clin Exp Ophthalmol] 2024 Jun; Vol. 262 (6), pp. 1755-1763. Date of Electronic Publication: 2024 Jan 15. |
| نوع المنشور: | Journal Article; Comparative Study |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 8205248 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1435-702X (Electronic) Linking ISSN: 0721832X NLM ISO Abbreviation: Graefes Arch Clin Exp Ophthalmol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Berlin ; New York : Springer-Verlag, c1982- |
| مواضيع طبية MeSH: | Recombinant Fusion Proteins*/administration & dosage , Receptors, Vascular Endothelial Growth Factor*/administration & dosage , Central Serous Chorioretinopathy*/drug therapy , Central Serous Chorioretinopathy*/diagnosis , Central Serous Chorioretinopathy*/physiopathology , Visual Acuity* , Intravitreal Injections* , Tomography, Optical Coherence* , Photochemotherapy*/methods , Angiogenesis Inhibitors*/administration & dosage , Fluorescein Angiography*, Humans ; Retrospective Studies ; Male ; Female ; Chronic Disease ; Treatment Outcome ; Middle Aged ; Follow-Up Studies ; Adult ; Photosensitizing Agents/administration & dosage ; Photosensitizing Agents/therapeutic use ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/therapeutic use ; Fundus Oculi ; Dose-Response Relationship, Drug ; Vascular Endothelial Growth Factor A/antagonists & inhibitors ; Retina/pathology |
| مستخلص: | Purpose: To compare the efficacy of brolucizumab, half-dose PDT, and aflibercept in treating chronic central serous chorioretinopathy (CSC). Methods: A retrospective cohort study with chronic CSC patients who underwent intravitreal injection of one shot of brolucizumab or aflibercept in the first 3 months, followed by pro re nata regimens or a single session of half-dose PDT, was retrospectively reviewed. The primary outcome measure was the proportion of eyes that achieved complete absorption of retinal fluid without requiring any rescue treatment. Secondary outcomes included changes in best-corrected visual acuity (BCVA), central retinal thickness (CRT), and central choroidal thickness (CCT). Results: A total of 54 consecutive patients were included in this study with 18 patients in each group. At months 1 and 2, the brolucizumab group exhibited the highest rate of complete retinal fluid resolution (61% and 77%), followed by the half-dose PDT group (56% and 72%), and lowest in the aflibercept group (28% and 33%), with statistically significant differences noted at month 2 (P = 0.012). The brolucizumab group also demonstrated the most significant reduction in CCT at months 1 and 2 among the three groups (P = 0.007 and 0.001). Recurrence of retinal fluid in the brolucizumab groups was predominantly observed at month 3. Conversely, the half-dose PDT group exhibited the most favorable anatomical results starting from month 3. Notably, mild vitritis was observed in one case from the brolucizumab group. Conclusions: Single injection of brolucizumab demonstrates trends of faster regression of persistent residual retinal fluid, greater CCT and CRT decline, and matched BCVA compared to half-dose PDT in the short term. (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.) |
| References: | van Rijssen TJ, van Dijk EHC, Yzer S et al (2019) Central serous chorioretinopathy: towards an evidence-based treatment guideline. Prog Retin Eye Res 73:100770. https://doi.org/10.1016/j.preteyeres.2019.07.003. (PMID: 10.1016/j.preteyeres.2019.07.00331319157) Gass JD (1967) Pathogenesis of disciform detachment of the neuroepithelium. Am J Ophthalmol 63(Suppl):1–139. Marmor MF (1988) New hypotheses on the pathogenesis and treatment of serous retinal detachment. Graefes Arch Clin Exp Ophthalmol 1226:548–552. https://doi.org/10.1007/BF02169203. (PMID: 10.1007/BF02169203) Cheung CMG, Lee WK, Koizumi H, Dansingani K, Lai TYY, Freund KB (2019) Pachychoroid disease. Eye (Lond) 33:14–33. https://doi.org/10.1038/s41433-018-0158-4. (PMID: 10.1038/s41433-018-0158-429995841) Daruich A, Matet A, Marchionno L, De Azevedo JD, Ambresin A, Mantel I, Behar-Cohen F (2017) Acute central serous chorioretinopathy: factors influencing episode duration. Retina 37:1905–1915. https://doi.org/10.1097/IAE.0000000000001443. (PMID: 10.1097/IAE.0000000000001443280677245642321) Chen SN, Hwang JF, Tseng LF, Lin CJ (2008) Subthreshold diode micropulse photocoagulation for the treatment of chronic central serous chorioretinopathy with juxtafoveal leakage. Ophthalmology 115:2229–2234. https://doi.org/10.1016/j.ophtha.2008.08.026. (PMID: 10.1016/j.ophtha.2008.08.02619041477) You EL, Hébert M, Jin TS, Bourgault S, Caissie M, Tourville É, Chen J, Ordóñez-Mena J, Dirani A (2023) Comparing interventions for chronic central serous chorioretinopathy: a network meta-analysis. Surv Ophthalmol 68:601–614. https://doi.org/10.1016/j.survophthal.2023.03.001. (PMID: 10.1016/j.survophthal.2023.03.00136931437) van Dijk EHC, Feenstra HMA, Bjerager J, Grauslund J, Boon CJF, Subhi Y (2023) Comparative efficacy of treatments for chronic central serous chorioretinopathy: a systematic review with network meta-analyses. Acta Ophthalmol 101:140–159. https://doi.org/10.1111/aos.15263. (PMID: 10.1111/aos.1526336178171) Tseng CC, Chen SN (2015) Long-term efficacy of half-dose photodynamic therapy on chronic central serous chorioretinopathy. Br J Ophthalmol 99:1070–1077. https://doi.org/10.1136/bjophthalmol-2014-305353. (PMID: 10.1136/bjophthalmol-2014-30535325680621) Lai FH, Ng DS, Bakthavatsalam M, Chan VC, Young AL, Luk FO, Tsang CW, Brelén ME (2016) A multicenter study on the long-term outcomes of half-dose photodynamic therapy in chronic central serous chorioretinopathy. Am J Ophthalmol 170:91–99. https://doi.org/10.1016/j.ajo.2016.07.026. (PMID: 10.1016/j.ajo.2016.07.02627519561) Artunay O, Yuzbasioglu E, Rasier R, Sengul A, Bahcecioglu H (2010) Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical study. Curr Eye Res 35:91–98. https://doi.org/10.3109/02713680903428306. (PMID: 10.3109/0271368090342830620136418) Semeraro F, Romano MR, Danzi P, Morescalchi F, Costagliola C (2012) Intravitreal bevacizumab versus low-fluence photodynamic therapy for treatment of chronic central serous chorioretinopathy. Jpn J Ophthalmol 56:608–612. https://doi.org/10.1007/s10384-012-0162-3. (PMID: 10.1007/s10384-012-0162-322915299) Khanani AM, Brown DM, Jaffe GJ, Wykoff CC, Adiguzel E, Wong R, Meng X, Heier JS, Investigators MERLIN (2022) MERLIN: phase 3a, multicenter, randomized, double-masked trial of brolucizumab in participants with neovascular age-related macular degeneration and persistent retinal fluid. Ophthalmology 129:974–985. https://doi.org/10.1016/j.ophtha.2022.04.028. (PMID: 10.1016/j.ophtha.2022.04.02835537533) Mukai R, Matsumoto H, Nagai K, Akiyama H (2022) Comparison of the regressive effects of aflibercept and brolucizumab on pigment epithelial detachment. BMC Ophthalmol 22:387. https://doi.org/10.1186/s12886-022-02617-2. (PMID: 10.1186/s12886-022-02617-2361758629520796) Dugel PU, Singh RP, Koh A, Ogura Y, Weissgerber G, Gedif K, Jaffe GJ, Tadayoni R, Schmidt-Erfurth U, Holz FG (2021) HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 128:89–99. https://doi.org/10.1016/j.ophtha.2020.06.028. (PMID: 10.1016/j.ophtha.2020.06.02832574761) Brown DM, Emanuelli A, Bandello F et al (2022) KESTREL and KITE: 52-week results from two phase III pivotal trials of brolucizumab for diabetic macular edema. Am J Ophthalmol 238:157–172. https://doi.org/10.1016/j.ajo.2022.01.004. (PMID: 10.1016/j.ajo.2022.01.00435038415) Dugel PU, Jaffe GJ, Sallstig P, Warburton J, Weichselberger A, Wieland M, Singerman L (2017) Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial. Ophthalmology 124:1296–1304. https://doi.org/10.1016/j.ophtha.2017.03.057. (PMID: 10.1016/j.ophtha.2017.03.05728551167) Liegl RG, Karcher H, Chetty-Mhlanga S, Igwe F, Freitas R (2023) The treatment patterns with brolucizumab in Germany (REALIZE) study: a retrospective cohort study based on longitudinal prescription data. Ophthalmol Ther 12:195–208. https://doi.org/10.1007/s40123-022-00596-7. (PMID: 10.1007/s40123-022-00596-736327000) Torres-Soriano ME, García-Aguirre G, Kon-Jara V, Ustariz-Gonzáles O, Abraham-Marín M, Ober MD, Quiroz-Mercado H (2008) A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (case reports). Graefes Arch Clin Exp Ophthalmol 246:1235–1239. https://doi.org/10.1007/s00417-008-0856-x. (PMID: 10.1007/s00417-008-0856-x18523796) Lim JW, Kim MU, Shin MC (2010) Aqueous humor and plasma levels of vascular endothelial growth factor and interleukin-8 in patients with central serous chorioretinopathy. Retina 30:1465–1471. https://doi.org/10.1097/IAE.0b013e3181d8e7fe. (PMID: 10.1097/IAE.0b013e3181d8e7fe20526231) Pitcher JD 3rd, Witkin AJ, DeCroos FC, Ho AC (2015) A prospective pilot study of intravitreal aflibercept for the treatment of chronic central serous chorioretinopathy: the CONTAIN study. Br J Ophthalmol 99:848–852. https://doi.org/10.1136/bjophthalmol-2014-306018. (PMID: 10.1136/bjophthalmol-2014-30601825595177) Fukuda Y, Sakurada Y, Matsubara M, Hasebe Y, Sugiyama A, Kikushima W, Kashiwagi K (2021) Comparison of outcomes between 3 monthly brolucizumab and aflibercept injections for polypoidal choroidal vasculopathy. Biomedicines 9:1164. https://doi.org/10.3390/biomedicines9091164. (PMID: 10.3390/biomedicines9091164345723508469297) Kitajima Y, Maruyama-Inoue M, Ikeda S, Ito A, Inoue T, Yanagi Y, Kadonosono K (2022) Short-term outcomes of switching to brolucizumab in Japanese patients with neovascular age-related macular degeneration. Jpn J Ophthalmol 66:511–517. https://doi.org/10.1007/s10384-022-00940-1. (PMID: 10.1007/s10384-022-00940-136149566) van Dijk EHC, Fauser S, Breukink MB et al (2018) Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: the PLACE trial. Ophthalmology 125:1547–1555. https://doi.org/10.1016/j.ophtha.2018.04.021. (PMID: 10.1016/j.ophtha.2018.04.02129776672) Ratanasukon M, Thongthong K, Bhurayanontachai P, Jirarattanasopa P (2013) Photoreceptor disruption in central serous chorioretinopathy treated by half-dose photodynamic therapy. Clin Ophthalmol 7:87–92. https://doi.org/10.2147/OPTH.S39584. (PMID: 10.2147/OPTH.S39584233459623548438) Bae SH, Heo JW, Kim C, Kim TW, Lee JY, Song SJ, Park TK, Moon SW, Chung H (2011) A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy. Am J Ophthalmol 152:784–92.e2. https://doi.org/10.1016/j.ajo.2011.04.008. (PMID: 10.1016/j.ajo.2011.04.00821742303) Sirks MJ, van Dijk EHC, Rosenberg N et al (2022) Clinical impact of the worldwide shortage of verteporfin (Visudyne®) on ophthalmic care. Acta Ophthalmol 100:e1522–e1532. https://doi.org/10.1111/aos.15148. (PMID: 10.1111/aos.15148353886199790583) Karakus SH, Basarir B, Pinarci EY, Kirandi EU, Demirok A (2013) Long-term results of half-dose photodynamic therapy for chronic central serous chorioretinopathy with contrast sensitivity changes. Eye (Lond) 27:612–620. https://doi.org/10.1038/eye.2013.24. (PMID: 10.1038/eye.2013.2423519277) |
| فهرسة مساهمة: | Keywords: Aflibercept; Brolucizumab; Chronic central serous chorioretinopathy; Half-dose PDT |
| المشرفين على المادة: | 0 (aflibercept) 0 (brolucizumab) |
| تواريخ الأحداث: | Date Created: 20240115 Date Completed: 20240520 Latest Revision: 20240520 |
| رمز التحديث: | 20240521 |
| DOI: | 10.1007/s00417-024-06373-5 |
| PMID: | 38224344 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder كن أول من يترك تعليقا!